[
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Mixed Late Afternoon",
    "summary": "Health care stocks were mixed late Thursday afternoon with the NYSE Health Care Index adding 0.1% an",
    "url": "https://finnhub.io/api/news?id=37eac18ea42409c92a18bb44a1de280b1dd229a7477a346d410a8f74f7b451db",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755806697,
      "headline": "Sector Update: Health Care Stocks Mixed Late Afternoon",
      "id": 136470396,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Health care stocks were mixed late Thursday afternoon with the NYSE Health Care Index adding 0.1% an",
      "url": "https://finnhub.io/api/news?id=37eac18ea42409c92a18bb44a1de280b1dd229a7477a346d410a8f74f7b451db"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Topples On A Surprise Setback For Its 99.9% Effective HIV Drug",
    "summary": "Gilead Topples On A Surprise Setback For Its 99.9% Effective HIV Drug",
    "url": "https://finnhub.io/api/news?id=a3824295118beddb2506986ed766c1505579d6561875e9d98d515969b873db0e",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755795363,
      "headline": "Gilead Topples On A Surprise Setback For Its 99.9% Effective HIV Drug",
      "id": 136490489,
      "image": "",
      "related": "GILD",
      "source": "DowJones",
      "summary": "Gilead Topples On A Surprise Setback For Its 99.9% Effective HIV Drug",
      "url": "https://finnhub.io/api/news?id=a3824295118beddb2506986ed766c1505579d6561875e9d98d515969b873db0e"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Needs Insurers to Cover New HIV Prevention Shot. CVS Isn’t Paying.",
    "summary": "The injection, called Yeztugo, is highly effective, but its list price is $28, 218 a year in the U.S.",
    "url": "https://finnhub.io/api/news?id=be6a70a6aff1c7fca4c0c3fb825b8b94f57db0bf9674ca31f395fafb6eb7f470",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755792900,
      "headline": "Gilead Needs Insurers to Cover New HIV Prevention Shot. CVS Isn’t Paying.",
      "id": 136471519,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "The injection, called Yeztugo, is highly effective, but its list price is $28, 218 a year in the U.S.",
      "url": "https://finnhub.io/api/news?id=be6a70a6aff1c7fca4c0c3fb825b8b94f57db0bf9674ca31f395fafb6eb7f470"
    }
  },
  {
    "ts": null,
    "headline": "Why Gilead Sciences (GILD) Shares Are Sliding Today",
    "summary": "Shares of biopharmaceutical company Gilead Sciences (NASDAQ:GILD) fell 3.5% in the morning session after reports that CVS Health will not be adding the company's new HIV prevention drug, Yeztugo, to its commercial insurance plans for now.",
    "url": "https://finnhub.io/api/news?id=cda0f070c6860ef709e1baabc1cbb555aea5d510916bab4ac6e9f2959c5ab48d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755789361,
      "headline": "Why Gilead Sciences (GILD) Shares Are Sliding Today",
      "id": 136467834,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Shares of biopharmaceutical company Gilead Sciences (NASDAQ:GILD) fell 3.5% in the morning session after reports that CVS Health will not be adding the company's new HIV prevention drug, Yeztugo, to its commercial insurance plans for now.",
      "url": "https://finnhub.io/api/news?id=cda0f070c6860ef709e1baabc1cbb555aea5d510916bab4ac6e9f2959c5ab48d"
    }
  },
  {
    "ts": null,
    "headline": "Coty, Gilead Sciences, Rent the Runway: Trending tickers",
    "summary": "Market Catalysts Host Julie Hyman recaps some of the trending tickers on Thursday, Aug. 21, including Coty (COTY), Gilead Sciences (GILD), and Rent the Runway (RENT). To watch more expert insights and analysis on the latest market action, check out more Market Catalysts.",
    "url": "https://finnhub.io/api/news?id=d6337f0db8ff607b5a74366b5da089a9a128c25fc0a28cedb53a649ed92697be",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755789142,
      "headline": "Coty, Gilead Sciences, Rent the Runway: Trending tickers",
      "id": 136467835,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Market Catalysts Host Julie Hyman recaps some of the trending tickers on Thursday, Aug. 21, including Coty (COTY), Gilead Sciences (GILD), and Rent the Runway (RENT). To watch more expert insights and analysis on the latest market action, check out more Market Catalysts.",
      "url": "https://finnhub.io/api/news?id=d6337f0db8ff607b5a74366b5da089a9a128c25fc0a28cedb53a649ed92697be"
    }
  },
  {
    "ts": null,
    "headline": "Stocks Pressured by Weak Walmart Earnings and Higher Bond Yields",
    "summary": "The S&P 500 Index ($SPX ) (SPY ) today is down by -0.40%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down by -0.64%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down by -0.39%. September E-mini S&P futures (ESU25 ) are down -0.43%, and September...",
    "url": "https://finnhub.io/api/news?id=4a1bbbb45b60f3119aafda279a4b27f5ba09dfdc78a6d13a7c9c9889718568a6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755785867,
      "headline": "Stocks Pressured by Weak Walmart Earnings and Higher Bond Yields",
      "id": 136469178,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "The S&P 500 Index ($SPX ) (SPY ) today is down by -0.40%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down by -0.64%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down by -0.39%. September E-mini S&P futures (ESU25 ) are down -0.43%, and September...",
      "url": "https://finnhub.io/api/news?id=4a1bbbb45b60f3119aafda279a4b27f5ba09dfdc78a6d13a7c9c9889718568a6"
    }
  },
  {
    "ts": null,
    "headline": "Update: Market Chatter: CVS Health Won't Cover Gilead's New HIV Prevention Drug Yet",
    "summary": "(Update to add Gilead's comment in the fourth paragraph) CVS Health (CVS) has decided not to incl",
    "url": "https://finnhub.io/api/news?id=4bc881779c3de61e9ec0223c99188902d719f2054e596f1329f340b0e310734c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755782468,
      "headline": "Update: Market Chatter: CVS Health Won't Cover Gilead's New HIV Prevention Drug Yet",
      "id": 136467654,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "(Update to add Gilead's comment in the fourth paragraph) CVS Health (CVS) has decided not to incl",
      "url": "https://finnhub.io/api/news?id=4bc881779c3de61e9ec0223c99188902d719f2054e596f1329f340b0e310734c"
    }
  },
  {
    "ts": null,
    "headline": "Gilead stock falls after CVS holds off adding HIV prevention shot to plans",
    "summary": "Investing.com -- Gilead Sciences (NASDAQ:GILD) stock fell 2.7% in pre-market trading Thursday after reports that CVS Health (NYSE:CVS) will not add the company’s new HIV prevention drug, Yeztugo, to its commercial plans for now.",
    "url": "https://finnhub.io/api/news?id=a116c6757a9c3aed11072c0198bee501deecfdc663cc8314e3efd6f55e4e2c3e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755780602,
      "headline": "Gilead stock falls after CVS holds off adding HIV prevention shot to plans",
      "id": 136467838,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Investing.com -- Gilead Sciences (NASDAQ:GILD) stock fell 2.7% in pre-market trading Thursday after reports that CVS Health (NYSE:CVS) will not add the company’s new HIV prevention drug, Yeztugo, to its commercial plans for now.",
      "url": "https://finnhub.io/api/news?id=a116c6757a9c3aed11072c0198bee501deecfdc663cc8314e3efd6f55e4e2c3e"
    }
  },
  {
    "ts": null,
    "headline": "Kite to Acquire Interius BioTherapeutics to Advance In Vivo Platform",
    "summary": "SANTA MONICA, Calif. & PHILADELPHIA, August 21, 2025--Kite has entered into a definitive agreement to acquire Interius BioTherapeutics, a privately held company developing in vivo CAR therapeutics.",
    "url": "https://finnhub.io/api/news?id=3c56df2ea8f0f02a4aeb291623554f97c6cf15d7ad45a3d0f34e8cb79766da25",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755779400,
      "headline": "Kite to Acquire Interius BioTherapeutics to Advance In Vivo Platform",
      "id": 136467839,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "SANTA MONICA, Calif. & PHILADELPHIA, August 21, 2025--Kite has entered into a definitive agreement to acquire Interius BioTherapeutics, a privately held company developing in vivo CAR therapeutics.",
      "url": "https://finnhub.io/api/news?id=3c56df2ea8f0f02a4aeb291623554f97c6cf15d7ad45a3d0f34e8cb79766da25"
    }
  },
  {
    "ts": null,
    "headline": "Dow Jones Futures Fall Amid Walmart Earnings, Meta News After Palantir-Led Rally Off Lows",
    "summary": "The major indexes bounced, but Palantir and many leaders still have sharp weekly losses. Walmart earnings loom.",
    "url": "https://finnhub.io/api/news?id=48aa0d5632071ec11c5eae818a3ec747da2c323973a306bb5039320176cc6515",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755778487,
      "headline": "Dow Jones Futures Fall Amid Walmart Earnings, Meta News After Palantir-Led Rally Off Lows",
      "id": 136467612,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "The major indexes bounced, but Palantir and many leaders still have sharp weekly losses. Walmart earnings loom.",
      "url": "https://finnhub.io/api/news?id=48aa0d5632071ec11c5eae818a3ec747da2c323973a306bb5039320176cc6515"
    }
  },
  {
    "ts": null,
    "headline": "Gilead dives into ‘in vivo’ cell therapy with $350M buyout of Interius",
    "summary": "The deal gives Gilead ownership of a technology that can genetically modify immune cells inside the body, an approach could potentially widen access to CAR-T treatment.",
    "url": "https://finnhub.io/api/news?id=c8c45f2beeead360266152c4507c1c24659d1486018f8cb066d985d64cdc820b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755777420,
      "headline": "Gilead dives into ‘in vivo’ cell therapy with $350M buyout of Interius",
      "id": 136467841,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "The deal gives Gilead ownership of a technology that can genetically modify immune cells inside the body, an approach could potentially widen access to CAR-T treatment.",
      "url": "https://finnhub.io/api/news?id=c8c45f2beeead360266152c4507c1c24659d1486018f8cb066d985d64cdc820b"
    }
  },
  {
    "ts": null,
    "headline": "Dow Jones Futures Fall After Palantir Leads Rally Off Lows; Walmart Earnings Due",
    "summary": "The major indexes bounced, but Palantir and many leaders still have sharp weekly losses. Walmart earnings loom.",
    "url": "https://finnhub.io/api/news?id=796f5eb99c5ec8435f3c6b6c8944efc18f6fbb8c1b1ee59fe263baeaea9870f8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755772898,
      "headline": "Dow Jones Futures Fall After Palantir Leads Rally Off Lows; Walmart Earnings Due",
      "id": 136452288,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "The major indexes bounced, but Palantir and many leaders still have sharp weekly losses. Walmart earnings loom.",
      "url": "https://finnhub.io/api/news?id=796f5eb99c5ec8435f3c6b6c8944efc18f6fbb8c1b1ee59fe263baeaea9870f8"
    }
  },
  {
    "ts": null,
    "headline": "Market Chatter: CVS Health Won't Cover Gilead's New HIV Prevention Drug Yet",
    "summary": "CVS Health (CVS) has decided not to include Gilead Sciences' (GILD) new HIV prevention drug, Yeztugo",
    "url": "https://finnhub.io/api/news?id=e63848e550ef812bca0552da187fba5b54b7291fa7137f25c22ab856146c21e4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755772465,
      "headline": "Market Chatter: CVS Health Won't Cover Gilead's New HIV Prevention Drug Yet",
      "id": 136467660,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "CVS Health (CVS) has decided not to include Gilead Sciences' (GILD) new HIV prevention drug, Yeztugo",
      "url": "https://finnhub.io/api/news?id=e63848e550ef812bca0552da187fba5b54b7291fa7137f25c22ab856146c21e4"
    }
  },
  {
    "ts": null,
    "headline": "Hartford Healthcare Fund Q2 2025 Commentary",
    "summary": "The Hartford Healthcare Fund (I Share) outperformed the S&P Composite 1500 Health Care Index during the quarter. Read more here.",
    "url": "https://finnhub.io/api/news?id=f8b7703fb46da00d8ea965f9f056688fcf2528cb789b78bb6f1c7c7ea46efb79",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755771900,
      "headline": "Hartford Healthcare Fund Q2 2025 Commentary",
      "id": 136458913,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/685006799/image_685006799.jpg?io=getty-c-w1536",
      "related": "GILD",
      "source": "SeekingAlpha",
      "summary": "The Hartford Healthcare Fund (I Share) outperformed the S&P Composite 1500 Health Care Index during the quarter. Read more here.",
      "url": "https://finnhub.io/api/news?id=f8b7703fb46da00d8ea965f9f056688fcf2528cb789b78bb6f1c7c7ea46efb79"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences to Buy Interius BioTherapeutics for $350 Million",
    "summary": "Gilead Sciences to Buy Interius BioTherapeutics for $350 Million",
    "url": "https://finnhub.io/api/news?id=e6f82f80d871123917d3437ed9683fc5d976b9817d124e158fd9cf7fa7c66d02",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755768600,
      "headline": "Gilead Sciences to Buy Interius BioTherapeutics for $350 Million",
      "id": 136490511,
      "image": "",
      "related": "GILD",
      "source": "MarketWatch",
      "summary": "Gilead Sciences to Buy Interius BioTherapeutics for $350 Million",
      "url": "https://finnhub.io/api/news?id=e6f82f80d871123917d3437ed9683fc5d976b9817d124e158fd9cf7fa7c66d02"
    }
  }
]